

Accepted Manuscript

Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells

Heikki Saari, Elisa Lázaro-Ibáñez, Tapani Viitala, Elina Vuorimaa-Laukkanen, Pia Siljander, Marjo Yliperttula

PII: S0168-3659(15)30132-2
DOI: doi: [10.1016/j.jconrel.2015.09.031](https://doi.org/10.1016/j.jconrel.2015.09.031)
Reference: COREL 7871

To appear in: *Journal of Controlled Release*

Received date: 2 June 2015
Revised date: 9 September 2015
Accepted date: 17 September 2015



Please cite this article as: Heikki Saari, Elisa Lázaro-Ibáñez, Tapani Viitala, Elina Vuorimaa-Laukkanen, Pia Siljander, Marjo Yliperttula, Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells, *Journal of Controlled Release* (2015), doi: [10.1016/j.jconrel.2015.09.031](https://doi.org/10.1016/j.jconrel.2015.09.031)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells

Heikki Saari^{a§}, Elisa Lázaro-Ibáñez^{a§}, Tapani Viitala^a, Elina Vuorimaa-Laukkanen^b, Pia Siljander^{a,c} and Marjo Yliperttula^{a*}

^aDivision of Pharmaceutical Biosciences, Centre for Drug Research, Faculty of Pharmacy, University of Helsinki, P.O. Box 56 (Viikinkaari 5E), 00014, Helsinki, Finland
Department of Chemistry and Bioengineering, Tampere University of Technology, P. O. Box 541 (Korkeakoulunkatu 8) FI33101 Tampere, Finland.

^cDivision of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, P.O. Box 56 (Viikinkaari 9), 00014, Helsinki, Finland

[§]equal contribution

*correspondence: marjo.yliperttula@helsinki.fi

Key words: extracellular vesicles, microvesicles, exosomes, paclitaxel, drug delivery, prostate cancer

Abstract

Background

Extracellular vesicles (EVs) are naturally occurring membrane particles that mediate intercellular communication by delivering molecular information between cells. In this study, we investigated the effectiveness of two different populations of EVs (microvesicle- and exosome-enriched) as carriers of Paclitaxel to autologous prostate cancer cells.

Methods

EVs were isolated from LNCaP- and PC-3 prostate cancer cell cultures using differential centrifugation and characterized by electron microscopy, nanoparticle tracking analysis, and western blot. The uptake of microvesicles and exosomes by the autologous prostate cancer cells was assessed by flow cytometry and confocal microscopy. The EVs were loaded with Paclitaxel and the effectiveness of EV-mediated drug delivery was assessed with viability assays. The distribution of EVs and EV-delivered Paclitaxel in cells was inspected by confocal microscopy.

Results

Our main finding was that the loading of Paclitaxel to autologous prostate cancer cell-derived EVs increased its cytotoxic effect. This capacity was independent of the EV population and the cell line tested. Although the EVs without the drug increased cancer cell viability, the net effect of enhanced cytotoxicity remained. Both EV populations delivered Paclitaxel to the recipient cells through endocytosis, leading to the release of the drug from within the cells. The removal of EV surface proteins did not affect exosomes, while the drug delivery mediated by microvesicles was partially inhibited.

Conclusions

Cancer cell-derived EVs can be used as effective carriers of Paclitaxel to their parental cells, bringing the drug into the cells through an endocytic pathway and increasing its cytotoxicity. However, due to the increased cell viability, the use of cancer cell-derived EVs must be further investigated before any clinical applications can be designed.

Download English Version:

<https://daneshyari.com/en/article/7862522>

Download Persian Version:

<https://daneshyari.com/article/7862522>

[Daneshyari.com](https://daneshyari.com)